Clinical Trials Logo

Clinical Trial Summary

Most patients who present with problem drinking also present with mood problems. Problem drinking and mood problems co-occurring together in individuals lead them to have more severe symptoms, greater disability and poorer quality of life than individuals with only problem drinking, and they pose a greater economic burden to society due to their higher use of health services. This study aims to assess the efficacy of a new, innovative and cost effective treatment strategy aimed at reducing the burden that these co-occurring conditions impose on the suffers and their families as well as the community and health systems.

In a recent pilot study of supportive text messages for patients with problem drinking and co-occurring depression, the investigators established that patients who received twice daily supportive text messages for three months had significantly less depressive symptoms than those who did not receive such messages. There was also a trend to finding that patients who received the supportive text messages were more likely to have higher alcohol free days than those who did not receive any supportive text messages.

This study seeks to extend the knowledge gained from the pilot study. A larger group of patients with alcohol use disorder and a depressive disorder will be randomly assigned to two groups. One group will receive supportive text messages for six months duration whilst the other group will receive no supportive text messages. The patients will be followed up at 3, 6, 9 and 12 months to determine which of the two groups have less alcohol and mood problems. It is anticipated that patients receiving supportive text messages will report significantly greater alcohol free days as well as significantly less relapses, hospitalizations and mood symptoms than those not receiving such messages.


Clinical Trial Description

Co-morbidity of alcohol use disorder (AUD) and mood disorders presents a great challenge to health systems and exacts a tremendous toll world-wide. Individuals with a dual diagnosis have more severe symptoms, greater disability and poor quality of life than those with either diagnosis alone, and pose a greater economic burden to society due to their higher use of treatment services. New, enhanced, efficient, innovative and cost effective treatment strategies aimed at reducing the burden that the disorders impose on the suffers and their families as well as the community and health systems are required. In a pilot trial of supportive text messages for patients with alcohol use disorders and co-morbid depression, the investigators established that patients who received twice daily supportive text messages for three months had significantly less depressive symptoms than those who did not receive such messages. There was also a trend to finding that patients who received the supportive text messages were more likely to have higher cumulative abstinence duration than those who did not receive any supportive text messages.

This research seeks to extend the knowledge gained from the pilot trial. A randomised trial will be conducted on a larger sample size of patients with alcohol use disorder and a co-morbid depressive disorder (including bipolar depression) for an extended duration (6 months of supportive text messages and 1 year follow-up instead of 3 months text messages with 6 months follow-up in the pilot trial). It is hypothesised that patients receiving supportive text messages will report significantly greater cumulative abstinence duration as well as significantly less relapses, hospitalizations and mood symptoms than those not receiving such messages. It is anticipated that this technology intervention for relapse prevention will be acceptable to patients as well as cost effective. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02404662
Study type Interventional
Source St Patrick's Hospital, Ireland
Contact
Status Active, not recruiting
Phase N/A
Start date March 2015
Completion date September 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Completed NCT02192931 - A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users Phase 4
Completed NCT00970372 - Dual-Diagnosis and Compulsory Treatment N/A
Completed NCT02520271 - Ostrobothnia Depression Study (ODS). A Naturalistic Follow-up Study on Depression and Related Substance Use Disorders N/A
Completed NCT00498550 - Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Phase 4
Not yet recruiting NCT06315660 - VR Based Therapy to Treat Anxiety in Dual Diagnosis N/A
Recruiting NCT06311838 - Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness N/A
Completed NCT00706901 - Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans N/A
Terminated NCT00169026 - Alcoholism and Schizophrenia: Effects of Clozapine Phase 4
Completed NCT01639872 - Clozapine for Cannabis Use in Schizophrenia Phase 4
Completed NCT00218582 - Effectiveness of Self-Help for Dually-Diagnosed Persons - 1 Phase 1/Phase 2
Recruiting NCT04105231 - Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use Phase 2
Completed NCT01964404 - Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment? Phase 1
Completed NCT00105768 - Effectiveness of Advisor-Teller Money Manager Phase 1/Phase 2
Completed NCT01514630 - Creatine as a Treatment Option for Depression in Methamphetamine Using Females Phase 4
Terminated NCT02189915 - Open-Label Creatine Study for Female Meth Users N/A
Completed NCT02082678 - Ondansetron for Bipolar Disorder and Alcohol Use Disorders Phase 4
Completed NCT01411085 - Risperidone and Desipramine in Alcohol Use and Schizophrenia Phase 2
Completed NCT00946348 - Cannabis and Schizophrenia: Self-Medication and Agonist Treatment Phase 1